ural arteriovenous fistulas (DAVFs) are abnormal communications between dural arteries and dural venous sinuses or subarachnoid veins and account for approximately 10%-15% of all intracranial vascular malformations.
D
ural arteriovenous fistulas (DAVFs) are abnormal communications between dural arteries and dural venous sinuses or subarachnoid veins and account for approximately 10%-15% of all intracranial vascular malformations. 11 Treatment of these lesions is based on the presenting symptoms and the presence of cortical venous reflux. The goal of treatment is surgical or endovascular occlusion of the fistula or fistulous nidus or at least the disconnection of the feeding vessels and the draining veins. Embolization of DAVFs can be achieved using a variety of embolic agents. Onyx (ethylene vinyl alcohol, ev3) was FDA approved in 2005 for preoperative embolization of cerebral arteriovenous malformations (AVMs), and has since been successfully used to treat other vascular lesions such as spinal AVMs and cerebral DAVFs as well as various tumors. 8 Although, endovascular "cure" of cerebral DAVFs using Onyx has been reported by multiple centers, the incidence of recurrence following initial angiographic obliteration has not been well established. 1, 7, 9, 12 In this article, we present a series of patients with cerebral DAVFs who underwent endovascular embolization with a curative intent. Our aim was to study the incidence and the factors affecting recurrence.
abbreviatioNs AVM = arteriovenous malformation; CVD = cortical venous drainage; DAVF = dural arteriovenous fistula; SRS = stereotactic radiosurgery. submitted January 9, 2015 The decision to perform a follow-up angiogram was at the discretion of the treating physician. "Angiographic cure" was attempted in all patients and was defined as occlusion of the fistula and absence of early filling of its venous drainage. Determination of whether the embolic material reached the common draining venous outlet was made by evaluation of both the pre-and postembolization angiograms as well as the final Onyx cast.
results
A total of 58 patients with cerebral DAVFs were treated at our institution from 2006 to 2013. Of these, 26 patients underwent endovascular embolization with the intention of complete angiographic cure. The breakdown of cases according to mode of treatment is displayed in Fig. 1 . A summary of the patient characteristics is provided in Table  1 . The mean age at presentation was 55.4 years (range 6 months-83 years). There were 15 males and 11 females. Clinical presentation included intraparenchymal hemorrhage in 6 patients (23%); pulsatile tinnitus in 4 patients (15%); and ataxia, headache, dizziness, proptosis, myelopathy, subdural hematoma, and subarachnoid hemorrhage in 1 patient each. DAVFs were incidentally detected in 9 of the 26 patients (34.6%). All procedures were completed in 1 session, except in 2 cases, which required 2 sessions of embolization to achieve angiographic cure.
The mean clinical follow-up was 15 months (2-39 months). Of the 13 patients with symptomatic presentation, clinical follow-up was available for 9. Improvement of symptoms was noted in 6 of the 9 patients (66.66%), and symptoms were stable in 2 patients (22.2%). One patient who presented with a ruptured DAVF with a large subdural hematoma worsened to persistent vegetative state despite evacuation of the hematoma.
Follow-up angiography was performed in 21 (80.7%) of 26 patients at a mean of 14 months after treatment (range 2-39 months). Recurrence of the fistula occurred in 3 (14.3%) of the 21 patients at a mean duration of 18 months after embolization. Upon careful review of the procedural angiograms, we noted that the Onyx cast had not reached the proximal portion of the venous outlet in 1 patient, but it did reach the draining vein in the other 2 cases (Fig. 2) . Of these 3 patients with recurrence, 1 patient underwent radiosurgery, and the other 2 patients were observed closely as there was no cortical venous reflux.
Nine patients in the present series had an angiographic follow-up of 12 or more months. Recurrence of the fistula occurred in 2 patients (22%) at a mean duration of 24 months after embolization. The probability of recurrence was plotted against time in a Kaplan-Meier graph (Fig. 3) . It shows that the probability of recurrence of the fistula is high in the 1st year after treatment, beyond which the probability of recurrence steeply decreases and is very low after 24 months of treatment.
discussion
The natural history of cranial DAVFs has been shown to be associated with 3 factors: presence of cortical venous drainage (CVD), mode of presentation, and presence of other high-risk angiographic features. Type III DAVFs in the Borden-Shucart classification system 3 and Types III, IV, and V in the Cognard 6 system are associated with CVD and are more likely to be symptomatic. Intracranial hemorrhage is believed to result from rupture of fragile veins subjected to cortical venous hypertension. On the other hand, nonhemorrhagic symptoms result from venous congestion and cerebral ischemia. 13, 14 Mode of presentation and the location of DAVF are closely related. Anterior cranial fossa DAVFs often present with hemorrhage since they almost always have CVD. However, they can also present with proptosis and chemosis if they drain into the cavernous sinus. Middle fossa fistulas are more likely to present with pulsatile tinnitus due to increased drainage through the sigmoid and transverse sinuses. Tentorial DAVFs have also been observed to carry a high risk of intracerebral hemorrhage, again, because they almost always have CVD. Brainstem and superior sagittal sinus DAVFs are more likely to present with nonhemorrhagic neurological deficits such as quadriparesis and lower cranial nerve palsies in the former and hydrocephalus, papilledema, seizures, and dementia in the latter.
14 Leptomeningeal drainage, variceal or aneurysmal venous dilatations, galenic drainage, and DAVFs of the petrosal and straight sinus have all been shown to carry a high risk of intracerebral hemorrhage, although this has not been validated in larger studies. 2, 4 Zipfel et al., in a systematic review, observed that symptomatic DAVFs have a high risk of intracerebral hemorrhage and death as compared with asymptomatic DAVFs. They concluded that Borden-Shucart Type I DAVFs without any CVD have a low risk for intracerebral hemorrhage (< 1% per year); asymptomatic Types II and III lesions with CVD carry an intermediate risk for bleed (1.4%-1.5% per year), and symptomatic Types II and III fistulas with CVD have a high risk of hemorrhage (7.4%-7.6% per year).
14 DAVFs can be treated by 3 modalities: surgery, endovascular embolization, or stereotactic radiosurgery (SRS). Lucas et al. performed a meta-analysis of the various treatment options for DAVFs. 10 They observed that in transverse-sigmoid sinus DAVFs, combined therapy (endovascular plus surgical treatment) proved significantly more effective than either therapy alone (p < 0.01). For lesions of the tentorial incisura, combined therapy and surgical obliteration alone proved superior to embolization (p < 0.001). For carotid-cavernous fistulas, treatment was primarily endovascular, with success rates of 62% and 78% for transarterial and transvenous approaches, respectively. For anterior fossa (ethmoidal) DAVFs, surgical obliteration was highly effective, with a success rate of 95%. The authors concluded that there was no single ideal treatment for DAVFs and that each patient should be managed individually. 10 In a systematic review of SRS for DAVFs, complete obliteration was observed in 56% and 75% of patients with and without cortical venous reflux, respectively. SRS may be a safe alternative for recurrent or refractory DAVFs.
5
Endovascular embolization with Onyx is effective, especially in complex fistulas. The advantage of Onyx is that it gradually precipitates in a radial fashion from outside inward, forming a radial cast. This creates a patent channel in the center of the cast that allows the Onyx to be injected slowly and accurately. The injection can be interrupted several times throughout the procedure to assess the extent of embolization.
8 Penetration and occlusion of the fistulous point and common venous outlet must occur for cure to be achieved. Failure to cast the fistula into the venous side can lead to late recurrence as observed in 1 case in the present study. In the other 2 cases that recurred and in which the Onyx cast reached the proximal portion of the common vein, we hypothesize that the cast may not have completely filled and occluded the lumen of the venous outlet. Absence of early venous drainage on the immediate postembolization angiogram may have table 1. summary of patient characteristics* been related to significant slowing of flow though the fistula rather than an actual cure. Incomplete casting with Onyx, and thus persistence of venous outlet, may have led to delayed recurrence of the fistula. Hence, it is essential to follow these patients closely with serial angiography for the first 2 years.
Our study has several limitations. It is a retrospective, single-institution study involving a small cohort of patients. Angiographic follow-up was available in only 80.7% of the patients. However, despite the limited followup, 14.3% of our patients with relatively long-term followup were found to have a recurrence. Thus, this is actually an underestimation of the true incidence of recurrence. Perhaps a more thorough follow-up may have yielded a better estimate of true recurrence rates following endovascular embolization.
conclusions
Recurrence following initial angiographic cure of DAVF is not uncommon. Incomplete penetration of the embolic material into the proximal portion of the venous outlet may lead to delayed recurrence. Long-term angiographic follow-up is highly recommended. 
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